美国FDA不良事件报告系统中死亡结局上市后报告的评价
共纳入1,053,716份死亡结局ICSR,其中治疗恶性肿瘤、疼痛和肾脏疾病的10种药物占所有致死性ICSR的近20%。来自行业赞助项目、中毒控制中心、诉讼和专科药房的ICSR分别占14%、6.5%、5.0%和3.3%,仅编码为「死亡」的ICSR更可能缺失结构化数据且叙述中关键信息较少。
要点
- FAERS中死亡结局ICSR数量庞大,10种药物占近20%。
- ICSR来源多样,行业赞助项目占14%,中毒控制中心占6.5%。
- 仅编码「死亡」的报告结构化数据缺失和叙述关键信息不足更常见。
核心结论
- 了解死亡结局ICSR的来源和特征有助于对FAERS数据进行有意义的评价和解读,即使最严重结局的报告质量也存在很大差异。
主要发现
- 研究期间共收到1,053,716份死亡结局ICSR。
- 治疗恶性肿瘤、疼痛和肾脏疾病的10种药物占所有致死性ICSR的近20%。
- 来自行业赞助项目、中毒控制中心、诉讼和专科药房的ICSR分别占所有致死性ICSR的14%、6.5%、5.0%和3.3%。
- 仅不良事件编码为「死亡」的ICSR更可能缺失结构化数据,且叙述中更少包含关键信息(如死因、病史和因果关系评估)。
临床怎么用
- 临床药学智能体在解读FAERS死亡结局报告时,应关注报告来源和ICSR质量差异,避免仅凭编码「死亡」的报告直接判断药物因果关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Adverse reactions with an outcome of death are inherently important for pharmacovigilance organizations to evaluate. Prior efforts to systematically evaluate individual case safety reports (ICSRs) with an outcome of death have been limited to high-level summaries. OBJECTIVE: The aim of this study was to characterize ICSRs with an outcome of death contained in the US FDA Adverse Event Reporting System (FAERS) database. METHODS: All ICSRs received through 31 December 2017 reporting an outcome of death were characterized by patient demographics, suspect product(s), adverse events, and reporter type. Using the ICSR's narrative and reporter information, we classified ICSRs by source to include those from industry-sponsored programs, poison control centers, specialty pharmacies, and litigation. Additionally, a random sample of ICSRs was evaluated for completeness of structured data fields and manually reviewed for the availability of key information in the narrative (i.e. cause of death, medical history, and causality assessment). RESULTS: Overall, 1,053,716 ICSRs with a death outcome were received in the study period. Ten medications treating conditions for malignancies, pain, and kidney disease accounted for nearly 20% of all fatal ICSRs. ICSRs originating from industry-sponsored programs, poison control centers, litigation, and specialty pharmacies accounted for 14%, 6.5%, 5.0%, and 3.3% of all fatal ICSRs, respectively. ICSRs in which the only adverse event coded was 'death' were more likely to be missing structured data and less likely to include key information in the narrative. CONCLUSION: Understanding the origins and characteristics of ICSRs with an outcome of death supports meaningful evaluations and interpretations of FAERS data. A wide variability in ICSR quality exists, even in those reports with the most serious outcome.
引用
- Marwitz K, Jones SC, Kortepeter CM, et al. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System. Drug Saf. 2020. PMID: 31981082. doi:10.1007/s40264-020-00908-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。